Pre-Clinical dosimetry and radiobiology modelling in Targeted Radionuclide Therapy
Position: Research Scientist (Post Doc)
Institution: Montpellier Cancer Research Institute (IRCM)
Location: Montpellier, France
Application closes at: Oct 31st, 2020 00:00
While external beam radiotherapy (EBRT) relies on established absorbed dose-response relationships, targeted radionuclide therapy (TRT) is still used as radioactive chemotherapy and it remains very difficult to predict its effectiveness or toxicity based on dosimetric indexes. The reasons being that dosimetry is more complex than for EBRT and that absorbed doses alone may not give account of efficacy or efficacy.
Biological effective dose (BED) and Equivalent uniform BED (EuBED) were introduced to give account of the protracted and non-uniform irradiation delivered by TRT. However, there are non- targeted effects (e.g. bystander and immune responses) which are not absorbed dose-related. To better understand and optimise clinical TRT, our team aim to develop new radiobiologic parameters that would consider these non-targeted effects, thereby associating the different phenomena that contribute to radiobiological observations post irradiation.
This project will combine experimental radiobiology experiments on available preclinical models combining vectors and isotopes (90Y, 177Lu, 225Ac) with refined absorbed dose assessment in order to identify the parameters (absorbed dose related or not) that contribute to radiobiological effect.
The current job offer on radiopharmaceutical dosimetry will cover radiation transport and absorbed dose effect modelling.